\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes ERC MSCA RI Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment Joint Research Center EIC EIE EIT Widening/Spreading Enhancing EU R&I COST Missions New European Bauhaus Horizon Europe HorizonEU L+F Digital Europe HPC AI Continent Cybersecurity Advanced Digital Skills Deployment: Best use of technologies European Digital Innovation Hubs ERC RI MSCAThe short survey that NCP Flanders is conducting to collect feedback on its services and suggestions on how they can be further improved is open for five more days.
The NCP Flanders team greatly appreciates it if you could take a few minutes of your time (if you haven’t done so yet) to provide your answers and suggestions via this link.
The survey is still open for answers until 13 October 2023.
The survey is anonymous and structured along three main chapters: NCP assistance, info sessions, and NCP website & LinkedIn. If the responding person indicates not to know one of these aspects, the survey will automatically continue with the next chapter.
Thank you very much for your highly appreciated feedback!
Your NCP Flanders Team
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
